The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours

2016 ◽  
Vol 240 (3) ◽  
pp. 256-261 ◽  
Author(s):  
Elodie Richard ◽  
Thomas Grellety ◽  
Valerie Velasco ◽  
Gaetan MacGrogan ◽  
Hervé Bonnefoi ◽  
...  
Keyword(s):  
Breast Tumours ◽  
Molecular Apocrine

scholarly journals Identification of molecular apocrine breast tumours by microarray analysis

Oncogene ◽  
2005 ◽  
Vol 24 (29) ◽  
pp. 4660-4671 ◽  
Author(s):  
Pierre Farmer ◽  
Herve Bonnefoi ◽  
Veronique Becette ◽  
Michele Tubiana-Hulin ◽  
Pierre Fumoleau ◽  
...  
Keyword(s):  
Microarray Analysis ◽  
Breast Tumours ◽  
Molecular Apocrine

Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast

2018 ◽  
Vol 72 (1) ◽  
pp. 7-11 ◽  
Author(s):  
Clare D'Arcy ◽  
Cecily M Quinn
Keyword(s):  
Androgen Receptor ◽  
Breast Carcinoma ◽  
Molecular Classification ◽  
Apocrine Carcinoma ◽  
Breast Tumours ◽  
Therapeutic Implications ◽  
Molecular Apocrine ◽  
Recent Advances ◽  
Triple Negative Breast Carcinoma ◽  
Definition Of

Pure apocrine carcinoma of the breast is rare and has been defined by using a combination of morphologic (apocrine morphology in >90% of tumour cells) and immunohistochemical criteria (oestrogen receptor (ER) and progesterone receptor (PR) negative and androgen receptor (AR) positive). Recent advances in the molecular classification of breast tumours have uncovered a subset of breast tumours associated with high expression of androgen receptor mRNA including the so-called ‘luminal androgen receptor (LAR) tumours’ and ‘molecular apocrine tumours’ (MATs). Recognition of these tumour subsets has opened potential avenues for therapies exploiting the AR pathway in triple negative breast carcinoma (TNBC). In this second part of our two-part review, we focus on the definition of pure apocrine carcinoma, recent advances in understanding the molecular apocrine signature in breast carcinoma, its relationship to pure apocrine carcinoma defined at the level of light microscopy and immunohistochemistry (IHC) and the therapeutic implications of androgen expression in TNBC. We complete the article with a summary of the utility of IHC in stratifying apocrine lesions of the breast.

scholarly journals Identification of molecular apocrine breast tumours by microarray analysis

2005 ◽  
Vol 7 (S2) ◽  
Author(s):  
P Farmer ◽  
H Bonnefoi ◽  
V Becette ◽  
M Tubiana-Hulin ◽  
P Fumoleau ◽  
...  
Keyword(s):  
Microarray Analysis ◽  
Breast Tumours ◽  
Molecular Apocrine

scholarly journals Classification of breast tumours into molecular apocrine, luminal and basal groups based on an explicit biological model

2018 ◽  
Author(s):  
Richard Iggo
Keyword(s):  
Expression Profiles ◽  
Mammary Tumorigenesis ◽  
Gene Expression Profiles ◽  
Biological Model ◽  
Rna Seq ◽  
Meaningful Improvement ◽  
Breast Tumours ◽  
Molecular Apocrine ◽  
Apocrine Metaplasia

ABSTRACTThe gene expression profiles of human breast tumours fall into three main groups that have been called luminal, basal and either HER2-enriched or molecular apocrine. To escape from the circularity of descriptive classifications based purely on gene signatures I describe a biological classification based on a model of the mammary lineage. In this model I propose that the third group is a tumour derived from a mammary hormone-sensing cell that has undergone apocrine metaplasia. I first split tumours into hormone sensing and milk secreting cells based on the expression of transcription factors linked to cell identity (the luminal progenitor split), then split the hormone sensing group into luminal and apocrine groups based on oestrogen receptor activity (the luminal-apocrine split). I show that the luminal-apocrine-basal (LAB) approach can be applied to microarray data (186 tumours) from an EORTC trial and to RNA-seq data from TCGA (674 tumours), and compare results obtained with the LAB and PAM50 approaches. Unlike pure signature-based approaches, classification based on an explicit biological model has the advantage that it is both refutable and capable of meaningful improvement as biological understanding of mammary tumorigenesis improves.

scholarly journals 109 Game Changing Magnetic Experience in Rural and Urban Wirral Peninsula - Our Experience with Magseed Localisation of Impalpable Breast Tumours and Axillary Nodes

2021 ◽  
Vol 108 (Supplement_2) ◽  
Author(s):  
T Arif ◽  
R Vinayagam ◽  
J M Lund ◽  
S Poonawala
Keyword(s):  
Incidental Finding ◽  
Breast Tumour ◽  
Axillary Node ◽  
Reliable Technique ◽  
Breast Tumours ◽  
Rural And Urban ◽  
Mean Size ◽  
The Right ◽  
A Prospective Study ◽  
Mean Time

Abstract Introduction Magseed is a novel localization technology in which a tiny seed is inserted to accurately mark the site of breast tumour. These can be detected intra-operatively by sentimag localization system. It aids localization of impalpable breast lesions improving margin clearance rates. Method A prospective study of first fifty Magseed localised breast tumour and axillary node excisions in Clatterbridge General Hospital. Results A total of 50 patients had 52 Magseed inserted. n = 14 was symptomatic, n = 35 was screen detected and n = 1 was an incidental finding on surveillance mammogram for a B3 lesion. 30 seeds were inserted on the right and 22 were inserted on the left (two were bilateral). 44 seeds were inserted under ultrasound guidance and the rest were targeted under stereo guidance (n = 8). Deployment of two resulted in malposition requiring wire localization. Mean age of subjects was 59.76 (range 31-81) years. Mean time to surgery after magseed insertion was 8.04 (range 1-27) days. Mean weight of the specimen was 48.57(range 10-264) gm. Mean size of the lesions was 20.32 (range 8-65) mm. Redo surgery for margin clearance was performed bringing the re-excision rate to 15.38% (n = 8). Conclusions We conclude that Magseed localization of breast tumours is a safe and reliable technique

scholarly journals The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

Nature ◽  
2012 ◽  
Vol 486 (7403) ◽  
pp. 346-352 ◽  
Author(s):  
Christina Curtis ◽  
◽  
Sohrab P. Shah ◽  
Suet-Feung Chin ◽  
Gulisa Turashvili ◽  
...  
Keyword(s):  
Breast Tumours
Sign in / Sign up

Export Citation Format

Share Document